Compare Citius Pharmaceuticals Inc (CTXR) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Noble Corporation plc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Noble Corporation plc trades at $40.19 (market cap $6.65B). The key difference: Noble Corporation plc is far larger — about 454.2× Citius Pharmaceuticals Inc's market cap, and Noble Corporation plc pays a 4.8% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | NE | |
|---|---|---|
Market Cap | $14.64M | $6.65B |
Sector | Health | Technology |
52-Week High | $1.82 | $54.37 |
52-Week Low | $0.53 | $25.70 |
Enterprise Value | $10.86M | $7.90B |
Dividend Yield | — | 4.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Noble Corporation (NE) trades at $41.79, up 4.55% with a bullish technical signal supported by moving averages. The company maintains solid fundamentals with $3.29B revenue, 7.17% net margin, and positive cash flow of $228M in 2025. Recent contract wins in Brunei and the UK Continental Shelf worth over $136M demonstrate operational momentum ahead of Q2 2026 earnings on July 27.
Analyst consensus suggests moderate upside with a $50 price target, though mixed earnings history and elevated P/E of 29.15 warrant caution. Key risks include offshore drilling market volatility and execution on new contracts, while institutional sentiment remains divided with 31% buy ratings versus 25% sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
